StockGuru Blog: IncreMental Advantage Initiates Coverage of The Immune Response Corporation – Price Target of $0.09 Per Share Accumulate Rating
IMNR - The Immune Response Corporation IncreMental Advantage, an equity research firm, has initiated coverage of The Immune Response Corporation (OTCBB: IMNR) with an Accumulate rating.“The current market capitalization is only $13.1 million. It is unusual to find such a company with two novel products in Phase II clinical trials.” “We believe the Company’s clinical programs and valuation justify a market capitalization of $200 million to $225 million. If we divide market valuation by the total number of shares outstanding at this time (current), the valuation is $0.31 to $0.38 per share. Dividing market capitalization by fully diluted shares outstanding…